Celcuity (NASDAQ:CELC) Price Target Raised to $25.00

Celcuity (NASDAQ:CELC) had its target price increased by stock analysts at Craig Hallum from $20.00 to $25.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. Craig Hallum’s price target points to a potential upside of 15.05% from the company’s current price.

Other equities analysts have also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Celcuity in a report on Thursday. Needham & Company LLC boosted their price target on Celcuity from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Stifel Nicolaus initiated coverage on Celcuity in a report on Thursday, February 22nd. They set a “buy” rating and a $40.00 price target for the company.

Celcuity Stock Performance

NASDAQ:CELC traded up $3.57 during mid-day trading on Thursday, hitting $21.73. 353,955 shares of the stock were exchanged, compared to its average volume of 214,252. The stock has a market capitalization of $525.87 million, a price-to-earnings ratio of -7.99 and a beta of 0.74. The company has a debt-to-equity ratio of 0.39, a quick ratio of 11.15 and a current ratio of 11.15. The firm’s 50-day simple moving average is $16.20 and its 200 day simple moving average is $13.51. Celcuity has a fifty-two week low of $8.39 and a fifty-two week high of $22.19.

Institutional Investors Weigh In On Celcuity

Hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC bought a new stake in Celcuity during the 2nd quarter worth $37,000. Bank of America Corp DE grew its position in Celcuity by 40.3% during the 4th quarter. Bank of America Corp DE now owns 3,159 shares of the company’s stock worth $44,000 after acquiring an additional 907 shares during the last quarter. BNP Paribas Arbitrage SNC grew its position in Celcuity by 9,962.2% during the 2nd quarter. BNP Paribas Arbitrage SNC now owns 4,528 shares of the company’s stock worth $50,000 after acquiring an additional 4,483 shares during the last quarter. California State Teachers Retirement System bought a new stake in Celcuity during the 2nd quarter worth $63,000. Finally, JPMorgan Chase & Co. bought a new stake in Celcuity during the 4th quarter worth $70,000. Institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.